Lantern Pharma Inc. · NASDAQ:LTRN
Lantern Pharma — The Future of Medicine: Open Medicine AI webinar (September 2026)
15 slides from Lantern Pharma's conference presentation, Sep 23, 2026
Slide 1: A multi-agentic platform for end-to-end therapeutic development
A multi-agentic platform for end-to-end therapeutic development Business model · Roadmap · Value proposition September 23, 2026 www.open-medicine.ai
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: What we will cover – slides and verbal
What we will cover – slides and verbal Market Customers & feedback 1 The size of the opportunity and the shift from 2 Who is buying, what they need, how they use AI pilots to full-scale adoption the platform, what power users tell us Live demo Roadmap 3 Differentiated capabilities, shown in real tim
Slide 4: We did not set out to build an AI company
We did not set out to build an AI company We set out to get cancer drugs to patients faster and with less capital — and built the tools we needed because they did not exist. LANTERN PHARMA — CLINICAL PROGRAMS LP-184 (zirdafulven) LP-300 LP-284 Starlight Therapeutics Phase 1b/2 · TNBC, bladder, GBM H
Slide 5: A Complementary Growth Engine
THE GROWTH RATIONALE BEHIND OPEN-MEDICINE AI A Complementary Growth Engine Open-Medicine AI lets our team build a major new category, agentic AI for drug development, alongside Lantern's core discovery and development business. CORE BUSINESS NEW CATEGORY & WHO IT SERVES Lantern Pharma Open-Medicine
Slide 6: “AI co-scientists are revolutionizing how research is done”
“AI co-scientists are revolutionizing how research is done” Artificial-intelligence tools might be able to propose theories and analyse data, but humans still need to decide what makes sense. — Elie Dolgin “ The bottleneck is in reliable validation. “ The most valuable part now is actually asking th
Slide 7: What We’ve Accomplished So Far
PROGRESS TO DATE What We’ve Accomplished So Far 01 02 03 Customer feedback loops Advisory board Security and scale Specific input from customers and Recruiting world-class advisors to Strengthened the security and power users on what's unique, what help architect our success and scalability of the c
Slide 8: How We See the Market Developing
MARKET BACKGROUND How We See the Market Developing Growing into a new category, marked by disruption and by acceleration in new drug candidates. AI REVENUE POOL IN DRUG R&D $10.6B DISRUPTION Agen?c AI Legacy so*ware and services stall $2.5B · 24%, from ~1% About $3.8B of today's $4.65B pool is flat t
Slide 9: A New Generation of Scientific Work
SIMULTANEOUS DISRUPTION & ENABLEMENT A New Generation of Scientific Work TRADITIONAL METHODS CO-SCIENTIST SYSTEMS One hypothesis at a time, in Five to ten hypotheses in parallel, at the → cost of one “ Every prior computational wave series made a single serial path cheaper. Value measured in headcou
Slide 10: One question, carried end to end
LIVE DEMONSTRATION One question, carried end to end 1 A question a developer would actually ask 2 The hand-off and active integration Which patients, which biomarker, and Context carries to the next co- why — reasoned the way a senior scientist without re-prompting: a bioinformatician would team, no
Slide 11: Who is using the platform…and what they tell us
Who is using the platform…and what they tell us Biopharma R&D teams Academic and translational labs Service providers Independent developers Target and biomarker questions Cohort building and omics analysis CROs, bioinformatics and regulatory Small teams running full across programs; translational w
Slide 12: Partnerships in pursuit, under discussion and being architected
Partnerships in pursuit, under discussion and being architected Biopharma co-development Patient & Disease Groups Co-scientists deployed inside a partner’s program, Curated knowledge and access to reinforce with shared learning on outcomes therapeutic journey and empower trial seeking Service-provid
Slide 13: Where Open-Medicine Goes Next
ROADMAP Where Open-Medicine Goes Next 01 New disease categories 02 Novel therapeutic modalities Neurodegenerative, immune, inflammatory, cardio- More tools for peptides, cell and gene therapy, and metabolic and psychedelic therapeutics. radioligands. 03 Trial docs and regulatory filings 04 Proactive
Slide 14: Every person on this call will at some point be a patient.
Every person on this call will at some point be a patient. That is the reason the company exists, and the reason we built these tools inside our own programs first. Open-Medicine AI is how we make them available to everyone else who is trying to get a therapy to a patient. QUESTIONS IR@lanternpharma
Slide 15: OPEN MEDICINE
OPEN @) MEDICINE
Lantern Pharma — The Future of Medicine: Open Medicine AI webinar (September 2026) on 6ix